Sichuan Kelun Pharmaceutical News

Colon Pharmaceuticals (002422): Generics drive innovation and innovation drive the future

HAITONG SECDec 30, 2024 20:02

Colon Pharmaceutical (002422): A major infusion leader seizing the opportunities of the times

guolianDec 5, 2024 18:32

Colon Pharmaceuticals (002422): Profits exceed expectations, SKB264 is about to be approved

cscNov 4, 2024 13:27

Colon Pharmaceutical (002422): The product font structure continues to work hard and the results of innovation are gradually realized

orient securitiesOct 31, 2024 00:00

Colon Pharmaceuticals (002422): Strong 3Q profit, 4Q peak season may drive full-year performance

htscOct 29, 2024 00:00

Colon Pharmaceutical (002422): Rapid growth in performance, looking forward to the implementation of innovative results

Aug 30, 2024 14:16

Colon Pharmaceutical (002422): The 1H24 API business performed well, and the impact of infusion collection was on a steady increase in target prices

Aug 30, 2024 00:00

Colon Pharmaceuticals (002422): Profit side growth exceeds expectations, innovation drives long-term improvement

Aug 16, 2024 00:00

Colon Pharmaceutical (002422): 1H24 net profit slightly exceeded expectations, focus on the progress of the API business

Aug 13, 2024 08:46

Colon Pharmaceuticals (002422): Q2 results slightly exceeded expectations, three runs drive efficient performance growth

Aug 13, 2024 00:00

Colon Pharmaceutical (002422): Three steps drive differentiation to accelerate transformation and move towards a new stage of innovation and growth

Aug 8, 2024 00:00

Colon Pharmaceuticals (002422): Innovation is on the right track, leading ADC commercialization is dawning

May 24, 2024 08:21

Colon Pharmaceutical (002422) 2023 Report Review: Multi-wheel Drive Steady Growth and Innovative Layout Usher in a Harvest Period

Apr 30, 2024 16:51

Colon Pharmaceutical (002422): Performance is in line with expectations, and the large infusion and API sector is growing steadily

Apr 28, 2024 21:11

Colon Pharmaceuticals (002422): Rapid performance growth focuses on pipeline clinical and commercialization promotion

Apr 27, 2024 09:46

Colon Pharmaceutical (002422): Excellent performance in the infusion business, innovation, transformation and acceleration of implementation

Apr 26, 2024 00:00

Colon Pharmaceutical (002422): Three steps drive performance growth, innovative R&D and efficient promotion

Apr 26, 2024 00:00

China Galaxy released a research report on April 24 stating that it gave Colon Pharmaceutical (002422.SZ) a recommended rating. The main reasons for the rating include: 1) Infusion continues to exceed expectations, demand is strong & structure is optimize

Zhitong FinanceApr 25, 2024 19:37

Colon Pharmaceuticals (002422): Continued strong trend in 1Q, all sectors attacked at full speed

Apr 25, 2024 00:00

Colon Pharmaceuticals (002422): Three-engine drive transcends Mylan

Jan 19, 2024 14:21